Oral and topical administration of a geranyl acetophenone attenuates DNCB-induced atopic dermatitis-like skin lesions in BALB/c mice.

Autor: Mohd Kasim VNK; Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, 43400, Serdang, Selangor, Malaysia., Lee YZ; Faculty of Applied Sciences, UCSI University, Cheras, 56000, Kuala Lumpur, Malaysia., Bakrin IH; Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, 43400, Serdang, Selangor, Malaysia.; Premier Integrated Labs Sdn Bhd, Pantai Hospital Kuala Lumpur, Bangsar, 59100, Kuala Lumpur, Malaysia., Hussain MK; Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, 43400, Serdang, Selangor, Malaysia., Israf DA; Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, 43400, Serdang, Selangor, Malaysia.; Institute of Bioscience, Universiti Putra Malaysia, 43400, Serdang, Selangor, Malaysia., Shaari K; Faculty of Science, Universiti Putra Malaysia, 43400, Serdang, Selangor, Malaysia.; Institute of Bioscience, Universiti Putra Malaysia, 43400, Serdang, Selangor, Malaysia., Tan JW; School of Science, Monash University Malaysia, 47500, Subang Jaya, Selangor, Malaysia., Lee MT; Faculty of Pharmaceutical Sciences, UCSI University, Cheras, 56000, Kuala Lumpur, Malaysia.; Graduate Institute of Pharmacology, College of Medicine, National Taiwan University, Taipei, 10051, Taiwan.; UCSI Wellbeing Research Centre, UCSI University, 56000, Kuala Lumpur, Malaysia., Tham CL; Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, 43400, Serdang, Selangor, Malaysia. chauling@upm.edu.my.; Institute of Bioscience, Universiti Putra Malaysia, 43400, Serdang, Selangor, Malaysia. chauling@upm.edu.my.
Jazyk: angličtina
Zdroj: Scientific reports [Sci Rep] 2024 Jul 31; Vol. 14 (1), pp. 17623. Date of Electronic Publication: 2024 Jul 31.
DOI: 10.1038/s41598-024-66601-0
Abstrakt: Atopic dermatitis (AD) is a chronic, allergic inflammatory skin disorder that lacks a definite cure. Using a mouse DNCB-induced AD-like skin lesions model, this study evaluated the potential therapeutic utility of tHGA as an oral and topical treatment for AD. Male BALB/c mice were sensitised and challenged with 1% and 0.5% DNCB on their shaved dorsal skin. Mice in the treatment group were administered tHGA (20, 40, and 80 mg/kg) orally three times per week for 2 weeks, or tHGA (0.2%, 1%, and 5%) topically once daily for 12 days. On day 34, the mice were euthanized, and blood and dorsal skin samples were obtained for analysis. All doses of orally and topically administered tHGA significantly improved scratching, epidermal thickness, blood eosinophilia and mast cell infiltration. There was a minor discrepancy between the two routes of administration, with orally treated tHGA showing significant reductions in Scoring of Atopic Dermatitis (SCORAD), tissue eosinophil infiltration, serum IgE and skin IL-4 levels with treatment of 40 and 80 mg/kg tHGA, whereas topically applied tHGA showed significant reductions in all dosages. These findings suggest that tHGA exhibited therapeutic potential for AD as both oral and topical treatment ameliorates AD-like symptoms in the murine model.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje